{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:26:07Z","timestamp":1779287167439,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) patients who are carriers of glucosylceramidase \u03b21 (GBA1) gene mutations typically have an earlier age at onset and a more aggressive disease course, with a higher burden of neuropsychological issues. The use of deep brain stimulation (DBS) in PD patients with disabling motor fluctuations and absence of dementia is a widespread therapeutic option, often with good results in terms of improvement in activities of daily living and quality of life. Although all PD patients, when fulfilling the common selection criteria for DBS, can benefit from this intervention, some studies have raised attention toward the fact that PD patients who are carriers of GBA1 variants may have a worse DBS outcome possibly due to an accelerated progression of cognitive decline. From this viewpoint, we summarize the current literature, highlighting the knowledge gaps and proposing suggestions for further research as well as for clinical practice in this timeframe of uncertainty related to using DBS in PD patients who are carriers of GBA1 variants.<\/jats:p>","DOI":"10.3389\/fneur.2023.1158977","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:26:22Z","timestamp":1681449982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Should we offer deep brain stimulation to Parkinson\u2019s disease patients with GBA mutations?"],"prefix":"10.3389","volume":"14","author":[{"given":"Carlo Alberto","family":"Artusi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Lopiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e187800","DOI":"10.1001\/jamanetworkopen.2018.7800","article-title":"Association of Subthalamic Deep Brain Stimulation with Motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease: a systematic review and meta-analysis","volume":"2","author":"Artusi","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1007\/s00415-012-6469-7","article-title":"Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease","volume":"259","author":"Weiss","year":"2012","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/mds.25535","article-title":"Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation","volume":"28","author":"Angeli","year":"2013","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3233\/JPD-171172","article-title":"GBA-associated Parkinson's disease: progression in a deep brain stimulation cohort","volume":"7","author":"Lythe","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2018.08.006","article-title":"Genetic background and outcome of deep brain stimulation in Parkinson's disease","volume":"64","author":"Rizzone","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mdc3.12795","article-title":"Deep brain stimulation in patients with mutations in Parkinson's disease-related genes: a systematic review","volume":"6","author":"de Oliveira","year":"2019","journal-title":"Mov Disord Clin Pract."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.26302","article-title":"Parkinson disease and subthalamic nucleus deep brain stimulation: cognitive effects in GBA mutation carriers","volume":"91","author":"Pal","year":"2022","journal-title":"Ann Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/mdc3.13185","article-title":"The successful three-year outcome of deep brain stimulation in Gaucher disease type 1 associated Parkinson's disease: a case report","volume":"8","author":"Racki","year":"2021","journal-title":"Mov Disord Clin Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.brs.2021.08.002","article-title":"G325R GBA mutation in Parkinson's disease: disease course and long-term DBS outcome","volume":"14","author":"Ledda","year":"2021","journal-title":"Brain Stimul"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","article-title":"Hematologically important mutations: Gaucher disease","volume":"35","author":"Beutler","year":"2005","journal-title":"Blood Cells Mol Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archneurol.2007.68","article-title":"Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders","volume":"65","author":"Mata","year":"2008","journal-title":"Arch Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson's disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fneur.2019.00419","article-title":"A review of cognitive outcomes across movement disorder patients undergoing deep brain stimulation","volume":"10","author":"Cernera","year":"2019","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fnsys.2013.00118","article-title":"Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease","volume":"7","author":"Jahanshahi","year":"2013","journal-title":"Front Syst Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-022-09540-9","article-title":"Deep brain stimulation in Parkinson disease: a meta-analysis of the long-term neuropsychological outcomes","author":"Bucur","year":"2022","journal-title":"Neuropsychol Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ana.26499","article-title":"Precision vs. personalized DBS for GBA-related Parkinson disease","volume":"92","author":"Fung","year":"2022","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","article-title":"Association of CSF Glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease","volume":"100","author":"Oftedal","year":"2022","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1158977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:26:24Z","timestamp":1681449984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1158977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":20,"alternative-id":["10.3389\/fneur.2023.1158977"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1158977","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1158977"}}